Open AccessCirculating Hematopoietic Progenitors in Patients with Primary Lung Cancer
Author(s) -
Shimizu Eiji,
Mukai Junnosuke,
Takaue Yoichi,
Ogura Takeshi
Publication year - 1990
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1990.tb02693.x
Subject(s) - haematopoiesis , lung cancer , medicine , progenitor cell , lung , oncology , cancer research , pathology , immunology , biology , stem cell , genetics
The levels of circulating hematopoietic progenitors were measured in 28 patients with primary lung cancer. The average numbers of progenitors per milliliter of blood were 33 (range 0–360) for colony‐forming unit‐granulocyte macrophage (CFU‐GM), 23 (range 0–140) for burst‐forming unit‐erythrocyte (BFU‐E), and 4 (range 0–50) for colony‐forming unit‐mixed lineages (CPU‐mix). No significant influence of age, sex, histological type, or clinical stage of the tumor on the progenitor levels was detected. After cytoreductive chemotherapy of the patients by treatment with cisplatin plus etoposide, the cells showed 6‐ to 50‐fold rebound overshoots, but no rebound was observed after treatment with cisplatin alone, cisplatin plus mitomycin C or cisplatin plus vindesine plus mitomycin C, or in 4 of 5 patients treated with cyclophosphamide plus adriamycin plus vincristine. Peripheral blood hematopoietic progenitors should be useful as an alternative source of stem cells for lung cancer patients treated with marrow ablative chemotherapy.